MRK.DE | Ticker Profile - Titan Protect

MRK.DE

Merck KGaA

Health Care · Pharmaceuticals · XETRA

$136.20

Data: 2026-05-09

✓ ETHICAL PASS

Unknown MOAT

HIGH

Data Confidence: 100.0%

Key Metrics

How this company measures up on the fundamentals that matter

Market Cap

$49.1B

Total market value of the company

Trailing P/E

18.81

Reasonably valued

Forward P/E

13.13

Based on estimated future earnings — lower means cheaper

Rev Growth

-3.1%

Year-over-year revenue change

Profit Margin

0.0%

How much profit the company keeps from each dollar of revenue

ROE

8.9%

Return on equity — how efficiently it uses shareholder money

Analyst Target

N/A

Recommendation

N/A

Consensus view from ? analysts covering this stock

About Merck KGaA

Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs, biotech, and pharmaceutical companies, as well as the industrial sector; reagents, consumables, devices, instruments, software, and services for research, production, and testing to lab water instruments, microbiology and biomonitoring products, test assays, analytical reagents, and flow cytometry kits and instruments.

Country: Germany Industry: Drug Manufacturers - Specialty & Generic

Ethical Screening

Five compliance checks based on AAOIFI standards — all must pass for ethical clearance

Business Activity

PASS

Core business does not involve prohibited activities

Debt Ratio

23.2% PASS

Debt must be below 33% of total assets

Cash Ratio

4.5% PASS

Interest-bearing cash below 33% of assets

Receivables

7.7% PASS

Receivables below 49% of assets

Revenue Purity

1.4% PASS

Non-compliant revenue below 5% — any excess requires purification

Valuation

Fair Value Est.

$40.57

What our model estimates this business is worth per share

Margin of Safety

-235.7%

Trading above fair value — no margin of safety

Rating

OPPORTUNITY

Overall assessment combining ethics, valuation, and quality

Percentile

92.7th

Ranks in the top 7% of our 13,571 screened universe

Ethical Score

84.2

Valuation Score

65.5

Quality Score

28.0

Combined

N/A

Trading at $113, 178% above fair value of $41. Passes all ethical screens. Ranks better than 89% of screened stocks.

Quantitative Intelligence

Statistical analysis of price behaviour, risk, and market regime — independent of fundamental data

Regime

MARKUP

Price trending up with increasing momentum

Sharpe Ratio

-0.267

Returns do not compensate for the risk — negative edge

Kelly Fraction

-0.0945

No positive edge detected — the data suggests staying out

Calmar Ratio

-0.265

Drawdown risk outweighs the returns — higher risk profile

Annual Return

-10.7%

Historical annualised return based on price data

Max Drawdown

-40.5%

Largest peak-to-trough decline — the worst it has been

HMM State

BEAR

Statistical model detects bearish conditions

Days in State

How long the current regime has persisted — longer means more stable

Market Data

Trading characteristics and market positioning

Beta

N/A

52W High

$N/A

52W Low

$N/A

Avg Volume

N/A

Average daily shares traded — higher means easier to buy and sell

Short Ratio

N/A

Days it would take all short sellers to cover — higher means more crowded

Short % Float

N/A

Div Yield

2.0%

Annual dividend as a percentage of the share price

EPS (TTM)

$6.00

Earnings per share over the last 12 months

Financial Health

Balance sheet strength and cash generation — the foundation of long-term value

Debt/Equity

41.76

Heavy leverage — higher financial risk if revenues decline

Current Ratio

N/A

Quick Ratio

N/A

Like current ratio but excludes inventory — stricter test

Gross Margin

N/A

Revenue left after cost of goods — higher means pricing power

Operating Margin

18.2%

Profit from core operations before interest and tax

Free Cash Flow

N/A

Negative — the business is spending more than it generates

Revenue (TTM)

N/A

Total revenue over the last 12 months

Net Income

N/A

Loss-making — spending exceeds revenue after all costs

Explore the Ethical Screener View Track Record

Data sourced from public filings and market feeds. Not financial advice. Updated: 2026-05-09

Before you go